Radiotherapy Clinical Trials 2023

Browse 35 Radiotherapy Medical Studies Across 56 Cities

2 Phase 3 Trial · 89 Radiotherapy Clinics

Reviewed by Michael Gill, B. Sc.
10 Radiotherapy Clinical Trials Near Me
Top Cities for Radiotherapy Clinical Trials
Image of Houston in Texas.
Houston
6Active Trials
University of Texas MD Anderson Cancer CenterTop Active Site
Image of New York in New York.
New York
5Active Trials
Memorial Sloan Kettering Cancer CenterTop Active Site
Radiotherapy Clinical Trials by Phase of TrialMost Recent Radiotherapy Clinical Trials

What Are Radiotherapy Clinical Trials?

Radiotherapy clinical trials focus on radiation treatments for cancer patients. Radiation has been used to treat cancer for decades and generally has good success rates, especially when combined with other treatments such as chemotherapy.

However, radiation therapy may also cause serious discomfort or even other health problems. Radiotherapy clinical trials may study how to change treatment to reduce these side effects (such as adjusting doses or treatment timelines), how to treat side effects directly, or how to make radiotherapy more effective in general. Some clinical trials study how to target cancer cells more effectively, reducing the risk of side effects.

Why Is Radiotherapy Being Studied In Clinical Trials?

Radiotherapy is an extremely effective treatment for many types of cancer, but it also has significant side effects. These may range from fatigue to nausea, hair loss, and headaches to problems with memory or speech.

In some cases, radiotherapy may affect other organs. Lung cancer patients, for example, often develop esophagitis or swelling in the esophagus. This can lead to hospitalization and even needing a feeding tube placed.

Radiotherapy clinical trials, therefore, not only study ways to make radiation therapy more effective but also how to decrease damage to surrounding tissues and organs.

How Does Radiotherapy Work?

Radiation therapy works by targeting cancer cells to destroy their DNA. When cells incur enough damage, they can no longer replicate (or replicate much more slowly). The body removes these damaged cells, slowing or stopping cancer growth.

To facilitate this cell damage, radiotherapy uses highly concentrated beams of light. These include protons, X-rays, electron beams, or gamma rays. In most cases, this is a targeted light treatment focused on the affected body part. Some types of radiation are administered through an injection, an oral medication, or a device placed inside the body.

What Are Some of The Breakthrough Clinical Trials Involving Radiotherapy?

2013: Lower, more frequent doses of radiation may be more effective at treating small-cell lung cancer — This study found that twice-daily radiation treatments over the course of three weeks were as effective at treating certain types of lung cancer as higher doses over a longer period. Additionally, radiation caused less damage and fewer long-term health problems when given on this regimen.

2021: Sculpting radiation beam may reduce side effects of radiation for lung cancer patients — This study found that curving a radiation beam during treatment for lung cancer patients reduced serious side effects. Radiotherapy treatments often cause esophageal inflammation, which can cause severe adverse effects for cancer patients, often leading to hospitalization and the need for a feeding tube.

Who Are The Key Opinion Leaders On Radiotherapy Clinical Trial Research?

Christopher L. Deufel, Ph.D. — A physicist in radiation oncology, Christopher Deufel is a leading researcher in radiation therapy and artificial intelligence technology in treating cancer. Dr. Deufel has researched new radiation techniques to improve the effectiveness of radiotherapy treatments while reducing side effects, particularly in brachytherapy.

Samuel Chao, MD — Samuel Chao is a leading expert in radiotherapy for brain cancer and malignancies and participates in research on treatments for brain and spinal tumors. Dr. Chao’s clinical research has included developing more effective treatments for adult and pediatric brain and spinal cancer and improving patient quality of life after treatment.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 3rd, 2021

Last Reviewed: September 16th, 2023

References1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7. https://pubmed.ncbi.nlm.nih.gov/267429982 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7. https://pubmed.ncbi.nlm.nih.gov/267429983 Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7. https://pubmed.ncbi.nlm.nih.gov/205303164 Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7. https://pubmed.ncbi.nlm.nih.gov/205303165 Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7. https://pubmed.ncbi.nlm.nih.gov/205303166 Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011 Nov 10;29(32):4294-301. doi: 10.1200/JCO.2011.36.4596. Epub 2011 Oct 3. https://pubmed.ncbi.nlm.nih.gov/219695037 Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O(2)(⋅-) and H(2)O(2)-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. Erratum in: Cancer Cell. 2017 Aug 14;32(2):268. https://pubmed.ncbi.nlm.nih.gov/283666798 Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O2⋅- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. Erratum In: Cancer Cell. 2017 Aug 14;32(2):268. https://pubmed.ncbi.nlm.nih.gov/283666799 Welsh JL, Wagner BA, van't Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, Yee NS, Bodeker KL, Du J, Roberts LJ 2nd, Drisko J, Levine M, Buettner GR, Cullen JJ. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013 Mar;71(3):765-75. doi: 10.1007/s00280-013-2070-8. Epub 2013 Feb 5. https://pubmed.ncbi.nlm.nih.gov/2338181410 Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, Roodvoets AGH, Nagtegaal ID, Beets-Tan RGH, Blomqvist LK, Fokstuen T, Ten Tije AJ, Capdevila J, Hendriks MP, Edhemovic I, Cervantes A, Nilsson PJ, Glimelius B, van de Velde CJH, Hospers GAP; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Jan;22(1):29-42. doi: 10.1016/S1470-2045(20)30555-6. Epub 2020 Dec 7. Erratum In: Lancet Oncol. 2021 Feb;22(2):e42. https://pubmed.ncbi.nlm.nih.gov/33301740